bioAffinity Technologies News Update, CyPath Lung Sales Ramp Up Month Over Month
Portfolio Pulse from Benzinga Newsdesk
bioAffinity Technologies, Inc. (NASDAQ:BIAF) reports a 21% increase in April sales of CyPath Lung, a noninvasive diagnostic test for early lung cancer detection, with expansion outside Texas. The company also announces new hires to support sales and patient coaching, and plans to present research at the ATS International Conference.

May 02, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
bioAffinity Technologies reports significant sales growth and strategic team expansions, indicating strong market acceptance and operational scaling.
The reported 21% month-over-month sales increase for CyPath Lung, expansion of sales outside Texas, and strategic hires in sales and patient support roles indicate strong market acceptance and operational scaling. These developments are likely to positively influence investor sentiment and stock price in the short term, reflecting the company's growth trajectory and market expansion efforts.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90